Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20170745 | 0.82 | HCRTR1 (0.42) | OPRM1OPRD1OPRK1HCRTR1HTR1A | |
| SCHEMBL14617397 | 0.81 | HTR1A (0.33) | HTR1DHTR1BOPRM1OPRD1OPRK1 | |
| SCHEMBL12945079 | 0.74 | HCRTR1 (0.44) | OPRM1OPRD1OPRK1HCRTR1HTR1A | |
| SCHEMBL19937935 | 0.73 | OPRM1 (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14161022 | 0.72 | HCRTR1 (0.37) | OPRM1OPRD1OPRK1HCRTR1 | |
| SCHEMBL13151725 | 0.71 | OPRM1 (0.36) | OPRM1OPRD1OPRK1HCRTR1 | |
| SCHEMBL13067353 | 0.71 | OPRM1 (0.36) | OPRM1OPRD1OPRK1HCRTR1 | |
| SCHEMBL13376201 | 0.71 | OPRM1 (0.36) | OPRM1OPRD1OPRK1HCRTR1 | |
| SCHEMBL12945081 | 0.70 | OPRD1 (0.40) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14161147 | 0.70 | HCRTR1 (0.40) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563726-B2 | Stereoselective reduction of a morphinone | NEKTAR THERAPEUTICS (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130018190-A1 | STEREOSELECTIVE REDUCTION OF A MORPHINONE | NEKTAR THERAPEUTICS (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018190-A1 | STEREOSELECTIVE REDUCTION OF A MORPHINONE | SORD, ADH1C, ADH1A | HTR1D 1343/4885HTR1B 976/4885OPRM1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.